Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Nanobiotix completes patient inclusion for Phase II/III trial of NBTXR3 in soft tissue sarcoma

Abstract:
NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that it has completed patient inclusion for the Phase II/III trial (Act.In.Sarc) of its lead product candidate, NBTXR3, in soft tissue sarcoma. The last patients are expected to start their treatment in two to three weeks.

Nanobiotix completes patient inclusion for Phase II/III trial of NBTXR3 in soft tissue sarcoma

Paris, France and Cambridge, MA | Posted on October 23rd, 2017

Elsa Borghi, Nanobiotix’s Chief Medical Officer commented: “We are pleased to have reached this important milestone in Nanobiotix’s soft tissue sarcoma study, and we look forward to reporting our first data next year.”

The pivotal international Phase II/III study in soft tissue sarcoma was launched in Europe and Asia in October 2014 and aims to evaluate the safety and the efficacy of NBTXR3, a first-in-class radio-enhancer that could potentially target most solid tumors. The Phase II/III study is a prospective, randomized, multi-center, open label and active controlled two-arm study of 156 patients with locally advanced soft tissue sarcoma.

The trial’s primary endpoint is the complete pathological response rate. The secondary endpoints are the objective response rate (ORR) by imaging (MRI); the evaluation of the safety profile in terms of clinical and laboratory adverse events; the tumor volume changes; the resection margins and the limb amputation rate. Furthermore, an exploratory analysis of the progression free survival is planned once the follow-up period has been completed for all treated patients.

Nanobiotix expects to present the results of its Phase II/III trial in soft tissue sarcoma in the first half of 2018.

For more information about the study: Clinical trial.gov and http://www.actinsarc.com/ .

####

About Nanobiotix
Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a late clinical-stage nanomedicine company pioneering novel approaches for the treatment of cancer. The Company’s first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy with a view to providing a new, more efficient treatment for cancer patients.
NanoXray products are compatible with current radiotherapy treatments and are meant to treat potentially a wide variety of solid tumors including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, etc., via multiple routes of administration.

NBTXR3 is being evaluated in: soft tissue sarcoma (STS), head and neck cancers, prostate cancer, and liver cancers (primary and metastases). Additionally, head and neck cancer and rectal cancer trials led by Nanobiotix’s Taiwanese partner, PharmaEngine, are underway in the Asia Pacific region. The Company filed in August 2016 for market approval (CE Marking) in Europe for its lead product NBTXR3.

In 2016 the Company started a new preclinical research program in Immuno-oncology with its lead product NBTXR3, which could have the potential to bring a new dimension to cancer immunotherapies.

Nanobiotix is listed on the regulated market of Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP). The Company’s Headquarters is based in Paris, France, with a U.S. affiliate in Cambridge, MA.

Disclaimer

This press release contains certain forward-looking statements concerning Nanobiotix and its business. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of Nanobiotix filed with the French Financial Markets Authority (Autorité des Marchés Financiers) under number D.17-0470 on April 28, 2017 (a copy of which is available on www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.

This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Nanobiotix shares in any country. At the moment NBTXR3 does not bear a CE mark and is not permitted to be placed on the market or put into service until NBTXR3 has obtained a CE mark.

For more information, please click here

Contacts:
Nanobiotix

Sarah Gaubert
Director, Communications & Public Affairs
+33 (0)1 40 26 07 55
/



Noël Kurdi
Director, Investor Relations
+1 (646) 241-4400
/
Media relations

France – Springbok Consultants
Marina Rosoff
+33 (0)6 71 58 00 34



United States – RooneyPartners
Marion Janic
+1 (212) 223-4017

Copyright © Nanobiotix

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

The first PE blown films with nanotubes hit the Chinese market April 26th, 2018

Watching nanomaterials form in 4D: Novel technology allows researchers to see dynamic reactions as they happen at the nanoscale April 26th, 2018

The dispute about the origins of terahertz photoresponse in graphene results in a draw April 26th, 2018

Nuclear radiation detecting device could lead to new homeland security tool: New device can detect gamma rays and identify radioactive isotopes April 25th, 2018

Govt.-Legislation/Regulation/Funding/Policy

Watching nanomaterials form in 4D: Novel technology allows researchers to see dynamic reactions as they happen at the nanoscale April 26th, 2018

Getting a better look at living cells April 25th, 2018

Graphene origami as a mechanically tunable plasmonic structure for infrared detection April 25th, 2018

Nuclear radiation detecting device could lead to new homeland security tool: New device can detect gamma rays and identify radioactive isotopes April 25th, 2018

Nanomedicine

Watching nanomaterials form in 4D: Novel technology allows researchers to see dynamic reactions as they happen at the nanoscale April 26th, 2018

Getting a better look at living cells April 25th, 2018

Biophysics -- lighting up DNA-based nanostructures April 25th, 2018

JPK reports on research of the Mestroni Lab at the University of Colorado Denver which use the JPK NanoWizard® AFM to help in the characterization of cardiomyopathies April 24th, 2018

Announcements

The first PE blown films with nanotubes hit the Chinese market April 26th, 2018

Arbe Robotics Selects GLOBALFOUNDRIES for its High-Resolution Imaging Radar to Enable Safety for Autonomous Cars: Arbe Robotics’ proprietary chipset leverages GF’s 22FDX® technology to deliver industry’s first real-time 4D imaging radar for level 4 and 5 autonomous driving April 26th, 2018

Watching nanomaterials form in 4D: Novel technology allows researchers to see dynamic reactions as they happen at the nanoscale April 26th, 2018

The dispute about the origins of terahertz photoresponse in graphene results in a draw April 26th, 2018

Nanobiotechnology

Watching nanomaterials form in 4D: Novel technology allows researchers to see dynamic reactions as they happen at the nanoscale April 26th, 2018

Getting a better look at living cells April 25th, 2018

Biophysics -- lighting up DNA-based nanostructures April 25th, 2018

JPK reports on research of the Mestroni Lab at the University of Colorado Denver which use the JPK NanoWizard® AFM to help in the characterization of cardiomyopathies April 24th, 2018

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project